Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [ Lu]Lu-PSMA-617 Radioligand Therapy.

 [ Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [ Lu]Lu-PSMA-617 RLT.

Head-to-head comparison of F-FDG and F-FES PET/CT for initial staging of ER-positive breast cancer patients.

Purpose: To compare the diagnostic performance of F-fluorodeoxyglucose (F-FDG) and F-fluoroestradiol (F-FES) positron emission tomography/computed tomography (PET/CT) for initial staging of estrogen receptor (ER) positive breast cancer.

Methods: Twenty-eight patients with ER-positive breast cancer underwent F-FDG and F-FES PET/CT for initial staging. Diagnostic performance and concordance rates were analyzed for both radiotracers.

Comparison of performance between an -FDG PET normal brain template and a commercial template using the software.

Purpose: The aim of this study was to create and validate a normal brain template of -fluorodeoxyglucose ( ) uptake using the MIMneuro software to improve clinical practice.

Approach: One hundred and nine volunteers underwent an positron emission tomography/computed tomography scan. Sixty-three participants with normal Alzheimer's disease (AD) biomarkers were used to create a template.

Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [F]F-FDG PET/CT in Patients with Liver Malignancies.

Purpose: To compare quantitative parameters and tumour detection rates of [ Ga]Ga-FAPI PET/CT with those of dedicated liver PET/MRI and F-FDG PET in patients with liver malignancies.

Procedures: Twenty-seven patients (29 imaging studies) with diagnosed or suspected liver malignancies who underwent [ Ga]Ga-FAPI-46 PET/CT, liver PET/MRI, and [F]FDG PET/CT between September 2020 and June 2021 were retrospectively analysed. MRI findings were used as the reference standard for diagnosis.

Abnormality Pattern of F-18 FDG PET Whole Body with Functional MRI Brain in Post-Acute COVID-19.

Purpose: The study aimed to investigate imaging abnormalities associated with post-acute COVID-19 using F-18 FDG PET/CT and PET/ rsfMRI brain.

Methods: We retrospectively recruited 13 patients with post-acute COVID-19. The post-acute COVID-19 symptoms and neuropsychiatric tests were performed before F-18 FDG PET/CT whole body with PET/rsfMRI brain.

Alterations in 18F-FDG PET/MRI and 15O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination: A Pilot Study.

Purpose: This study aimed to investigate functional abnormalities in the brain of patients with neurological adverse effects following COVID-19 (coronavirus disease 2019) vaccination using 18F-FDG PET/MRI and 15O-water PET.

Methods: Eight patients (1 man and 7 women, aged 26-47 years [median age, 36.5 years]) who experienced neurological symptoms after the first COVID-19 vaccination underwent CT, MRI, 18F-FDG PET/MRI, and 15O-water PET of the brain.

Intense 68Ga-FAPI-46 Activity in Lesions of Recurrent Ovarian Clear Cell Carcinoma That Were Negative on FDG PET/CT Study.

A 55-year-old woman with recurrent ovarian clear cell carcinoma who underwent complete surgical staging and completed chemotherapy session approximately 7 months before. She presented with increased CA-125 levels. 68Ga-FAPI-46 PET showed significantly higher tumor-to-background contrast of recurrent intra-abdominal node metastases and distant metastases, which were undetectable in the 18F-FDG PET.

Head-to-Head Comparison of Ga-FAPI-46 and F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study.

Ga-conjugated fibroblast activation protein inhibitor (Ga-FAPI) has become an attractive agent for PET. This study aimed to compare Ga-FAPI-46 PET/CT with F-FDG PET/CT for detecting primary cancer and metastatic lesions in patients with head and neck squamous cell carcinoma (HNSCC). Twelve patients and 28 patients with HNSCC underwent Ga-FAPI-46 and F-FDG PET/CT for initial staging and recurrence detection, respectively.

Ga-FAPI-46 PET/MR Detects Recurrent Cholangiocarcinoma and Intraductal Papillary Mucinous Neoplasm in a Patient Showing Increasing CEA with Negative F-FDG PET/CT and Conventional CT.

A patient with intrahepatic cholangiocarcinoma who underwent hepatic resection with completed neoadjuvant chemotherapy presented with increased CEA levels. Previous whole abdominal and chest CT scan revealed no evidence of local recurrence or metastasis.  Ga-FAPI-46 PET showed significantly higher tumor-to-background contrast of recurrent tumor and nodal metastasis, which were undetectable in the FDG PET or conventional CT scan.

The Evaluation of Tau Deposition with [F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Background: Some studies have reported the effectiveness of [F]PI-2620 as an effective tau-binding radiotracer; however, few reports have applied semiquantitative analysis to the tracer. Therefore, this study's aim was to perform a semiquantitative analysis of [F]PI-2620 in individuals with normal cognition and patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Methods: Twenty-six cognitively normal (CN) subjects, 7 patients with AD, and 36 patients with MCI were enrolled.

C-Pittsburgh compound B and F-THK 5351 positron emission tomography brain imaging in cognitively normal individuals.

Abnormal beta-amyloid plaques and tau protein accumulation are the core pathologic features of Alzheimer's disease. However, the accumulation of these proteins is also common in cognitively normal elderly people. Therefore, this study is aimed to evaluate the amyloid and tau accumulation in the cognitively normal population.

Analysis of amyloid and tau deposition in Alzheimer's disease using C-Pittsburgh compound B and F-THK 5351 positron emission tomography imaging.

This study aims to determine the deposition of C-Pittsburgh compound B (C-PiB) and F-THK 5351 using a normal database of the optimal cut-off-points for standardized uptake value ratios (SUVRs) in Alzheimer's disease (AD) patients. Sixteen AD patients and 24 cognitively normal individuals were enrolled in this study. The optimal cutoff points for the SUVR from the normal database were used for quantitative analysis.

Clinical impact of quantitative [O] HO PET/CT myocardial perfusion imaging on decision-making regarding invasive management of coronary artery disease.

Background: This study was performed to determine the impact of oxygen-15-labeled water ([O] HO) positron emission tomography/computed tomography (PET/CT) myocardial perfusion imaging (MPI) on referral for invasive coronary angiography (ICA) and revascularization.

Methods: This study involved 57 patients who underwent [O] HO PET/CT MPI for evaluation of coronary artery disease (CAD). Data of referral for ICA and revascularization, clinical symptoms, and cardiac events within 6 months after MPI were assessed.

F-THK 5351 and C-PiB PET of the Thai normal brain template.

Objectives: The aim of the study was to create a local normal database brain template of Thai individuals for C-Pittsburgh compound B (C-PiB) and F-THK 5351 depositions using statistical parametric mapping (SPM) software, and to validate and optimize the established specific brain template for use in clinical practice with a highly reliability and reproducibility.

Methods: This prospective study was conducted in 24 healthy right-handed volunteers (13 men, 11 women; aged: 42-79 years) who underwent F-THK 5351 and C-PiB PET/CT scans. SPM was used for the F-THK 5351 and C-PiB PET/CT image analysis.

Evaluation of Imaging Windows for Tau PET Imaging Using F-PI2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer's Disease Patients.

Background: The study aimed to evaluate the appropriate uptake-timing in cognitively normal individuals, mild cognitive impairment (MCI), and Alzheimer's disease (AD) patients, using F-PI 2620 dynamic PET acquisition.

Methods: Thirty-four MCI patients, 6 AD patients, and 24 cognitively normal individuals were enrolled in this study. A dynamic F-PI 2620 PET study was conducted at 30-75 minutes post-injection in these groups.

Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.

Reporter gene systems can serve as therapy targets. However, the therapeutic use of reporters has been limited by the challenges of transgene delivery to a majority of cancer cells. This study specifically assesses the efficacy of targeting human somatostatin receptor subtype 2 (hSSTR2) with peptide receptor radionuclide therapy (PRRT) when a small subpopulation of cells bears the transgene.

Accuracy of FDG-PET/CT for Detection of Incidental Pre-Malignant and Malignant Colonic Lesions - Correlation with Colonoscopic and Histopathologic Findings.

Purpose: We evaluated all PET/CTs acquired for patients without a primary diagnosis of colorectal cancer, and compared results for those who had subsequent colonoscopy within 6 months, to assess the accuracy of FDG PET/CT for detection of incidental pre-malignant polyps and malignant colon cancers.

Materials And Methods: Medical records of 9,545 patients who underwent F-18 FDG PET/CT studies over 3.5 years were retrospectively reviewed.

Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.

Background: FDG PET/CT is at an equivocal stage to recommend for staging of colorectal cancer as compared to contrast-enhanced CT (ceCT). This study was intended to evaluate the value of FDG PET/ceCT in colorectal cancer staging as compared to ceCT alone.

Materials And Methods: PET/ceCT was performed for 61 colorectal cancer patients who were prospectively enrolled in the study.

Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT.

Purpose: The aim of this study was to compare C11 choline and F18 FDG PET/CT, gadoxeticenhanced 3T MRI and contrastenhanced CT for diagnosis of hepatocellular carcinoma (HCC).

Materials And Methods: Twelve chronic hepatitis B patients suspected of having HCC by abdominal ultrasonography received all diagnostic modalities performed within a oneweek timeslot. PET/CT results were analyzed visually by two independent nuclear medicine physicians and quantitatively by tumor to background ratio (T/B).

A case report of hyperfunctioning metastatic thyroid cancer and rare I-131 avid liver metastasis.

Thyroid cancer is usually, relatively hypofunctional; most patients with thyroid cancer are clinically euthyroid. The combination of thyroid cancer and thyrotoxicosis is not common. We herein, report a case of follicular thyroid cancer with hyperfunctioning metastasis in a 43-year-old woman who presented with thyrotoxicosis, a cold right thyroid nodule, and low I-131 uptake at the thyroid bed.

18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.

Background: Selection of the best treatment option for non-small cell lung cancer (NSCLC) depends on optimal initial staging.

Objective: Evaluate the clinical impact of 18F-FDG PET/CT on the management of Thai patients with NSCLC.

Material And Method: Twenty-four patients with NSCLC underwent FDG PET/CTfor initial staging.

Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.

Hypoxia is associated with resistance to radiotherapy and chemotherapy. Functional imaging of hypoxia in non-small cell lung cancer (NSCLC) could allow early assessment of tumor response and guide subsequent therapies. Epidermal growth factor receptor (EGFR) inhibition with erlotinib reduces hypoxia in vivo.